SHIFT Newsroom · GLOBAL
Emugrobart obesity development discontinued: registry entry lags announcement
Chugai announced on 28 September 2026 that obesity development of emugrobart would stop.
Chugai announced on 28 September 2026 that Roche would discontinue obesity development of emugrobart (GYM329/RO7204239) after an interim assessment of the phase 2 GYMINDA study. The company said clinically meaningful weight-loss objectives were unlikely to be achieved. It reported no new safety signals. These statements come from a company announcement, not a full published trial analysis.
The ClinicalTrials.gov record NCT06965413, last updated on 9 September 2026, still showed active, not recruiting when checked on 3 October. That older status should not be read as evidence that the obesity development programme is continuing.
Chugai is preparing to resume development in spinal muscular atrophy. That is a separate indication and does not establish an obesity treatment or UK access.
SHIFT’s take
A trial register can lag a later company decision. The discontinued obesity programme should not be presented as an approaching treatment option.